Insmed, Inc. (NASDAQ:INSM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have received an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twenty have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $205.7727.

A number of equities analysts have weighed in on INSM shares. Wedbush set a $203.00 target price on Insmed in a research note on Thursday, December 18th. HC Wainwright cut their price objective on Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Leerink Partners restated an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Wells Fargo & Company set a $195.00 target price on shares of Insmed in a research note on Thursday, December 18th. Finally, Jefferies Financial Group set a $269.00 price target on shares of Insmed in a research note on Wednesday, December 10th.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elizabeth M. Anderson sold 10,000 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $195.87, for a total value of $1,958,700.00. Following the completion of the transaction, the director owned 63,729 shares of the company’s stock, valued at $12,482,599.23. The trade was a 13.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 286,100 shares of company stock valued at $52,595,894 in the last three months. 3.00% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

Hedge funds and other institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC raised its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. Kingsview Wealth Management LLC boosted its stake in shares of Insmed by 2.7% in the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 60 shares in the last quarter. Choreo LLC grew its holdings in shares of Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 65 shares during the last quarter. ORG Partners LLC raised its position in Insmed by 12.7% in the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 74 shares during the period. Finally, Spire Wealth Management raised its position in Insmed by 11.5% in the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 80 shares during the period.

Insmed Stock Up 1.3%

Shares of NASDAQ:INSM opened at $161.42 on Friday. The firm has a fifty day moving average price of $187.73 and a two-hundred day moving average price of $153.96. The company has a market cap of $34.43 billion, a price-to-earnings ratio of -26.08 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. Insmed has a one year low of $60.40 and a one year high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company’s quarterly revenue was up 52.4% on a year-over-year basis. During the same quarter last year, the business posted ($1.27) EPS. Analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.